Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its growing portfolio of synthetic viral controls with the launch of a synthetic RNA control for H5N1 Influenza A, which is one of the causes of Highly Pathogenic Avian Influenza (HPAI) or bird flu, covering 99.9% of hemagglutinin (HA) and neuraminidase (N
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks